Moomoo AI 已提取核心信息
On February 29, 2024, TC BioPharm (Holdings) PLC, an emerging growth company listed on The Nasdaq Stock Market, reported a significant update to its executive compensation structure. The company's Remuneration Committee approved the issuance of new options to purchase American Depositary Shares (ADSs) to its executive officers and non-employee directors under the 2021 Shares Option Scheme. This move also included the cancellation of all previously issued share options to these individuals. Non-employee directors were granted options to purchase 41,760 ADSs each, while the CFO, Martin Thorp, received options for 177,122 ADSs, and the CEO, Bryan Kobel, was granted options for 381,606 ADSs. The exercise price for these options was set at $1.09 per ADS, equivalent to the closing price on January 31, 2024. All options vested immediately upon issuance. This strategic decision aligns with the company's aim to incentivize its leadership team and align their interests with those of the shareholders.
On February 29, 2024, TC BioPharm (Holdings) PLC, an emerging growth company listed on The Nasdaq Stock Market, reported a significant update to its executive compensation structure. The company's Remuneration Committee approved the issuance of new options to purchase American Depositary Shares (ADSs) to its executive officers and non-employee directors under the 2021 Shares Option Scheme. This move also included the cancellation of all previously issued share options to these individuals. Non-employee directors were granted options to purchase 41,760 ADSs each, while the CFO, Martin Thorp, received options for 177,122 ADSs, and the CEO, Bryan Kobel, was granted options for 381,606 ADSs. The exercise price for these options was set at $1.09 per ADS, equivalent to the closing price on January 31, 2024. All options vested immediately upon issuance. This strategic decision aligns with the company's aim to incentivize its leadership team and align their interests with those of the shareholders.
2024年2月29日，在纳斯达克股票市场上市的新兴成长型公司TC BioPharm（Holdings）PLC报告了其高管薪酬结构的重大更新。该公司的薪酬委员会批准了根据2021年股票期权计划向其执行官和非雇员董事发行购买美国存托股票（ADS）的新期权。此举还包括取消先前向这些人发行的所有股票期权。非雇员董事获准每人购买41,760份美国存托证券的期权，而首席财务官马丁·索普获得了177,122份美国国债的期权，首席执行官布莱恩·科贝尔获得了381,606份美国存托证券的期权。这些期权的行使价定为每份ADS1.09美元，相当于2024年1月31日的收盘价。所有期权在发行后立即归属。这一战略决策符合公司的目标，即激励其领导团队，使他们的利益与股东的利益保持一致。
2024年2月29日，在纳斯达克股票市场上市的新兴成长型公司TC BioPharm（Holdings）PLC报告了其高管薪酬结构的重大更新。该公司的薪酬委员会批准了根据2021年股票期权计划向其执行官和非雇员董事发行购买美国存托股票（ADS）的新期权。此举还包括取消先前向这些人发行的所有股票期权。非雇员董事获准每人购买41,760份美国存托证券的期权，而首席财务官马丁·索普获得了177,122份美国国债的期权，首席执行官布莱恩·科贝尔获得了381,606份美国存托证券的期权。这些期权的行使价定为每份ADS1.09美元，相当于2024年1月31日的收盘价。所有期权在发行后立即归属。这一战略决策符合公司的目标，即激励其领导团队，使他们的利益与股东的利益保持一致。
有用
没用